Through the Eye Clinic's study centre, we offer a variety of new, innovative treatment options that are not yet available in routine clinical practice. This provides patients with treatment options for diseases that were previously considered untreatable.

Below you will find the current range of studies offered by the Eye Clinic, sorted by entity and study status. If you have any questions or require further information on individual studies, please do not hesitate to contact our study team.

Age-related macular degeneration

I. ASCENT

Phase 3 study on the efficacy and safety of subretinal injection of RGX-314 as gene therapy in patients with neovascular age-related macular degeneration (nAMD).
EudraCT Number: 2023-503666-23-00

II TIGER

Phase 3 study on the efficacy and safety of vitrectomy, subretinal tissue plasminogen activator and intravitreal gas administration for the treatment of submacular haemorrhage in nAMD.
EudraCT Number: 2020-004917-10

III. OTX-TKI-2023-303

Phase 3 study of the efficacy and safety of intravitreal OTX-TKI (axitinib implant) in patients with nAMD.

IND 161586

IV. ARCHER II

Phase 3 study of the efficacy and safety of intravitreal ANX007 administered by intravitreal injection in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

EudraCT Number: 2024-515022-88-00

IND 130381

Diabetic retinopathy

I. CRIMSON

Phase 2b efficacy and safety study of intravitreal BI 764524 in patients with diabetic ischaemic maculopathy with moderate to severe non-proliferative diabetic retinopathy.
EudraCT Number: 2023-508891-12-00

Endocrine orbitopathy

I. ARGX-113-2309

Phase 3 study on the efficacy and safety of efgartigimod PH20 SC in patients with endocrine orbitopathy

EudraCT Number: 2023-509198-22-00

Age-related macular degeneration

I. VELODROME

Phase 3 pivotal study on the efficacy and safety of the "port delivery system" (ranibizumab) in nAMD.
EudraCT number: 2020-001313-20

II PORTAL

Phase 3 study on the efficacy and safety of the "Port Delivery System" (ranibizumab) in nAMD.
EudraCT number: 2020-004427-16

Retinal vein occlusions

I. CORALA II

Long-term need for ranibizumab injections with or without early targeted peripheral laser photocoagulation for the treatment of macular oedema due to retinal central retinal vein occlusion.
EudraCT number: 2020-000681-42

Retinal artery occlusions

I. REVISION

Phase 3 study on the efficacy and safety of early reperfusion therapy with intravenous alteplase to restore vision in acute retinal central retinal artery occlusion (REVISION).

EudraCT number: 2021-000183-29

Glaucoma

I. STARLIFE

Registry study (after approval and market launch) on the Minijet implant in adult patients with open-angle glaucoma. Collection of safety, performance and usability data up to 24 months after surgery.

Vitreoretinal lymphoma

I. DECODE VRL study

Multicentre implementation and clinical validation of a standardised, innovative molecular biological diagnostic for vitreoretinal lymphoma.

Intraocular lenses (IOL)

I. Alcon

Clinical evaluation of the EDoF Vivity intraocular lens in patients after successful vitrectomy for rhegmatogenous retinal detachment (RRD) and concomitant cataract.

Progressive myopia in children

I. AIM

Myopia in children aged 8-12 years, treatment with low-dose atropine eye drops.
EudraCT number: 2020-001575-33

II GAME

A sub-study of the AIM study:

Genetic influence on the effect of atropine to reduce myopia progression in children.
EudraCT number: 2020-001575-33

Age-related macular degeneration

I. MACUSTAR

Identification of progression and progression parameters in intermediate age-related macular degeneration.
NCT number: NCT03349801

II FALCON

A 52-week phase 4 study to evaluate the efficacy and safety of two different brolucizumab 6 mg dosing regimens in patients with refractory nAMD.
EudraCT number: 2019-004767-53

III. BI 13360007

Phase II study: Safety, tolerability and pharmacodynamics of single intravitreal doses and multiple intravitreal doses of BI 836880 in neovascular age-related macular degeneration (nAMD).
EudraCT number: 2017-001221-40

IV. ALXN2040-GA-201

Phase 2 study to determine the dose range of danicopan (ALXN2040) in patients with geographic atrophy (GA) due to age-related macular degeneration (AMD). EudraCT number: 2021-001198-22

V. GALTOS

Long-term observational study of geographic atrophy: a non-interventional study to describe the demographics, baseline characteristics and outcomes of patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in clinical practice.
Study protocol number: GAL-21-NIS

VI SHORE

Phase 3 study of the efficacy and safety of intravitreal OPT-302 in combination with ranibizumab compared to ranibizumab alone in patients with nAMD.
EudraCT number: 2020-004736-24

by arrangement